
Asylia Therapeutics: A biotech firm innovating immune-modulating therapies for diverse diseases.
Founded with a mission to transform scientific advances into safe and effective medicines, Asylia Therapeutics is a private development-stage biotechnology company. The company focuses on novel immune-modulating therapies targeting autoimmune diseases, cancer, and infectious diseases. Asylia's innovative platform centers on a drug pipeline designed to modulate antigen presentation to the immune system, aiming to produce unprecedented anti-tumor responses and other therapeutic benefits.
Asylia Therapeutics has attracted notable investors and key figures in the biotech industry, contributing to its rapid progress and recognition. The company's achievements include significant advancements in their drug pipeline, demonstrating promising preclinical results in modulating immune responses. Asylia's impact lies in its potential to revolutionize treatment paradigms for challenging diseases, offering hope for more effective and targeted therapies.

Asher Bio
asherbio.com

Arialys Therapeutics
arialysrx.com

Lapix Therapeutics
lapix.com

Aristea Therapeutics

Inimmune
inimmune.com

Halia Therapeutics

Fuse Biotherapeutics
fusebiotx.com

Therabiol

LTZ Therapeutics

Athos Therapeutics
athostx.com

Exalys Therapeutics

Arisan Therapeutics
arisanthera.com

Modulus Therapeutics

Asalyxa Bio

ImmuneSensor Therapeutics
immunesensor.com
Companies similar to Asylia Therapeutics include Asher Bio, Arialys Therapeutics, Lapix Therapeutics and Aristea Therapeutics.
Asylia Therapeutics was founded in 2019.
Asylia Therapeutics' headquarters is located in Houston, TX, US.
Asylia Therapeutics' most recent funding round was for $14.5M (USD) in May 2021.
As of May 25, 2021, Asylia Therapeutics has raised a total of $22.7M (USD).
Asylia Therapeutics has 8 employees as of Feb 5, 2024.